Low-Dose Subcutaneous Anti-CD38 Antibodies With Fewer Blood Cell Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD38 antibodies require high dosages and volumes for intravenous administration due to binding to red blood cells, leading to side effects like hemolytic anemia and thrombocytopenia, and are not suitable for subcutaneous administration, limiting their convenience and effectiveness in treating autoimmune diseases and hematologic cancers.
Innovation Solution
Administering isolated anti-CD38 antibodies with specific CDR sequences subcutaneously at low dosages and volumes, ranging from 0.03 to 0.6 mg/kg and 1 to 3 mL, to effectively target CD38-expressing cells while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CD38 antibodies are administered at high dosages to achieve therapeutic efficacy, then the treatment effectiveness is improved, but side effects such as hemolytic anemia and thrombocytopenia increase
Solution Approach 1:
The patent applies parameter changes by modifying the dosing regimen from high doses (10-20 mg/kg) to low doses (0.03-0.6 mg/kg), and by changing the administration route from intravenous to subcutaneous. This fundamental parameter change allows achieving therapeutic efficacy while avoiding the harmful effects associated with high-dose intravenous administration, particularly hemolytic anemia and thrombocytopenia
2Quantity of substance
If high volumes of anti-CD38 antibodies are administered for intravenous therapy, then sufficient drug delivery is achieved, but the treatment becomes unsuitable for subcutaneous administration
Solution Approach 1:
The patent changes the administration route parameter from intravenous to subcutaneous, which fundamentally alters the required volume parameters. By administering low doses (0.03-0.6 mg/kg) subcutaneously in small volumes (1-3 mL), the treatment becomes suitable for home administration while maintaining sufficient drug delivery to achieve therapeutic effects
3Quantity of substance
If intravenous administration is used to deliver anti-CD38 antibodies, then high dosages can be delivered, but patient convenience and healthcare costs increase
Solution Approach 1:
The patent changes the administration route from intravenous to subcutaneous and reduces the dosage parameter (0.03-0.6 mg/kg vs. 10-20 mg/kg), enabling patients to self-administer at home. This eliminates the need for infusion center visits, reducing time loss and healthcare costs while maintaining effective drug delivery through the optimized low-dose subcutaneous regimen
Data Source
AI summary
Methods of administering isolated anti-CD38 antibodies at low dosages subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.